Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered Into the Australian Register of Therapeutic Goods (ARTG) for use against COVID-19
MicroSafe Care Australia received approval for their patented and trademarked Nanocyn Disinfectant & Sanitizer, which is manufactured by Sonoma using its patented Microcyn Technology, to be entered into the Australian Register of Therapeutic Goods (ARTG) for use against SARS-CoV-2 (COVID-19).
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, and its partner, the MicroSafe Group, Dubai, announce an important break-through in the fight of the global coronavirus pandemic. MicroSafe Care Australia received approval for their patented and trademarked Nanocyn® Disinfectant & Sanitizer, which is manufactured by Sonoma using its patented Microcyn® Technology, to be entered into the Australian Register of Therapeutic Goods (ARTG) for use against SARS-CoV-2 (COVID-19). Claims that a disinfectant has a virucidal effect must be expressly permitted by the Australian Therapeutic Goods Administration before being used in consumer advertising (including on the label) in Australia.
Recently, Sonoma announced that it had successfully closed an Asset Purchase Agreement with MicroSafe Group, for the exclusive rights of the Microcyn® technology-based disinfectant for sale in the Australian market under the brand name Nanocyn® and the European and Middle Eastern markets under the brand name MicroSafe®.
“We have been fighting global pandemics for nearly 20 years with our safe and non-toxic Microcyn® based disinfectant and we are very pleased with the test results and subsequent approval of the SARS-CoV-2 (COVID-19) label claim for our Nanocyn® disinfectant in Australia. The label claim comes with a 30 second virucidal kill time on hard surfaces, a landmark kill time for a non-toxic disinfectant,” Mrs. Safa Qadumi, Founder and CEO of the MicroSafe Group Dubai, said.
“We have known for years that our Microcyn® Technology is effective against a number of pathogens, including viruses, so we are pleased to get this acknowledgement from the ARTG that our technology is effective in killing COVID-19,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. She continued, “As the pandemic has spread around the world, we are excited to work with partners like MicroSafe Group to provide a safer environment for people during this difficult time. As an international company selling products in 53 countries around the world, we are continuously seeking additional partners to expand our domestic and global reach in distributing our products.”
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 53 countries worldwide and the company actively seeks new distribution partners. The company has offices in Petaluma, California and Woodstock, Georgia, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected].
About MicroSafe Group
The MicroSafe Group has operations in several international countries with its head office in Dubai, United Arab Emirates. With several regional offices in the Middle East, as well as MicroSafe Care Australia, MicroSafe Group is able to provide innovative solutions to a wide range of industries and healthcare providers. The MicroSafe Group promotes only those products it believes will truly revolutionize healthcare – products that will enrich the lives of patients and healthcare professionals all over the world. Interested distributors may contact the MicroSafe Group at [email protected]. More information can be found at www.microsafe.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “promise,” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks resulting from the global COVID-19 pandemic, that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn® and Microdacyn60® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005780/en/